logo
  

PRIMEPULSE SE Sets Price Range Of Planned IPO At EUR 22-27/ Share

PRIMEPULSE SE, a technology-oriented investment holding based in Munich, on Friday specified the price range for its planned initial public offering or IPO at 22 euros to 27 euros per share.

The offer encompasses 5 million shares from a capital increase and an overallotment option of 750 thousand shares from the principal shareholders' existing holdings. Assuming complete placement of all shares offered, the placement volume is expected to be between 126.5 euros and 155.3 million euros, of which the company will receive between 110.0 million euros and 135.0 million euros as gross issuing proceeds.

The offer period is from October 22 to 31, 2018. The initial listing on the Frankfurt Stock Exchange is planned for November 06.

The company noted that the principal shareholders, Stefan Kober, Raymond Kober, and Klaus Weinmann, through ABCON Holding GmbH, will remain majority shareholders after the IPO. The goal is a free float of about 17 to 20 percent after the IPO, the company said.

The approval of securities prospectus is expected in the course of the day.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT